Therini Bio
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
2108 N St PMB 4963, Sacramento, Californ...Phone Number
(858) 414-1105Website
www.therinibio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Therini Bio
Located in South San Francisco at Lilly Gateway Labs, Therini is a vascular biology company focused on discovering and developing therapeutics targeting fibrin, a new biological target for neurological and peripheral diseases. Therini is a spin-out from the Gladstone Institutes based on technology discovered in the laboratory of Dr. Katerina Akassoglou, PhD at Gladstone Institutes, UCSF, and UCSD.Explore more
Therini Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Therini Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Therini Bio is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Therini Bio
Earning: See what the market has to say on Therini Bio recently announced quarterly report
Funding: Get notified immidiatlly once Therini Bio has new funding data
Product Launch: Get notified when Therini Bio launches new products
Check if Therini Bio has recently received funding, and reach out quickly before it becomes old news!
Click to see if Therini Bio had a recent Job posting/layoffs
Therini Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Therini Bio
Find 2 more new buyers
Compare Similar Companies to Therini Bio
Compare insights from companies similar to Therini Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Therini Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Therini Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Therini Bio.
Therini Bio financials insights
Gather financial insights about Therini Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series A
$36M
2025
Series A
$39M
Therini Bio Tech Stack
A closer look at the technologies used by Therini Bio
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Funding
Therini Bio News & Media
Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease
Therini Bio announced the dosing of the first patient in their Phase 1b trial evaluating THN391 in Alzheimer's DiseaseAngelini Ventures Invests into $39 Million Series A Extension Round for Therini Bio, a Clinical Stage Company Developing Fibrin-targeting Immunotherapies for Neurodegenerative Diseases
Rome, Italy, 14 May 2025 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and Digital Health, today announces its participation in a $39 million extension of the Series A financing round for Therini Bio, a US-based clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction.Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline
Therini Bio raised a $39M Series A financing, bringing the Series A total to $75M, from top-tier investors to commence THN391 Ph 1b AD and DME studiesTherini Bio Announces Positive Phase 1a Trial Results Evaluating THN391 for Neurodegenerative Diseases
Therini Bio's novel approach to treating neurodegenerative diseases yielded positive results in a Phase 1a study evaluating its lead candidate, THN391.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Therini Bio
Sign Up For FreeTo access detailed company insights
Located in South San Francisco at Lilly Gateway Labs, Therini is a vascular biology company focused on discovering and developing therapeutics targeting fibrin, a new biological target for neurological and peripheral diseases. Therini is a spin-out from the Gladstone Institutes based on technology discovered in the laboratory of Dr. Katerina Akasso... Read More
